Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 3% less
These brands contain the same active ingredient (Lynestrenol). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Lynotril is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Polymenorrhoea: Take 1 tablet daily on days 14 to 25 of the cycle. Premenstrual syndrome: Take 1 tablet daily on days 4 to 25 of the cycle. Endometriosis: Take 1 to 2 tablets daily for at least 6 months. Selected cases of endometrial carcinoma: Take 6 to 10 tablets daily for prolonged periods. Benign breast disease: Take 1 tablet daily on days 14 to 25 of the cycle for at least 3 to 4 months. Menorrhagia and metrorrhagia: Take 1 tablet daily on days 14 to 25 of the cycle; bleeding usually ceases within a few days after starting treatment. The course is then repeated for the next 3 menstrual cycles, with 1 tablet taken daily on days 14 to 25 of each cycle. If the complaints do not disappear during or after this treatment, further diagnostic evaluation is needed. Selected cases of primary and secondary amenorrhoea and oligomenorrhoea: Treatment should begin with an estrogen, for example 0.02 to 0.05 mg of ethinylestradiol daily for 25 days. Alongside this, 1 tablet of Lynestrenol is taken daily on days 14 to 25. Withdrawal bleeding usually occurs within 3 days after treatment stops. Treatment is then resumed for a second cycle starting on day 5 of this withdrawal bleeding, with the estrogen given on days 5 to 25 of the cycle and Lynestrenol again taken as 1 tablet daily on days 14 to 25. This course should be repeated for at least one more cycle. Suppression of menstruation, ovulation, and ovulation pain (dysmenorrhoea): Treatment with 1 tablet daily should ideally start on day 1 of the cycle, and no later than day 5. It can be continued for many months without tablet free days. If breakthrough bleeding occurs despite treatment, the dose should be raised to 2 or 3 tablets daily for 3 to 5 days. Postponement of menstruation: Treatment with 1 tablet daily should ideally start 2 weeks before menstruation is expected. If started less than 1 week before the expected onset, the dose should be 2 to 3 tablets daily, though in that case a delay of more than 1 week is not advisable. Starting treatment later raises the risk of breakthrough bleeding, so it should not begin later than 3 days before the expected onset of menstruation. As an adjunct to estrogen therapy in the pre and postmenopausal period, to help prevent endometrial hyperplasia: Take half to 1 tablet daily for 12 to 15 days each month, for example during the first 2 weeks of every calendar month, while the estrogen is given daily without tablet free intervals at the lowest effective dose.
Side Effects
During continuous Orgatril treatment, breakthrough bleeding or spotting is common (over 10 per cent of patients) in the first two months, tapering off gradually thereafter. With cyclic treatment, breakthrough bleeding and spotting occur occasionally (1 to 10 per cent), and a temporary dose increase controls it in most cases. Other side effects seen commonly (over 10 per cent) include changes in libido (either increased or decreased), nausea or other digestive upset, and weight gain. Side effects seen occasionally (1 to 10 per cent) or rarely (under 1 per cent) include headache or migraine, dizziness, nervousness, depression, increased sweating, acne, excess hair growth, patchy skin darkening, rash, itching, jaundice, changes in blood lipoprotein levels, abnormal liver function tests, absent periods, irregular periods, reduced glucose tolerance, breast pain, and fluid retention. Most of these effects are temporary and, in many cases, mild.
Cautions & Contraindications
Warnings & Precautions
Chloasma is occasionally seen during the use of estrogen and/or progestagen containing preparations, especially in women with a history of chloasma gravidarum. In women with a tendency to chloasma, exposure of the skin to natural or artificial sunlight may induce or aggravate the condition. Occasionally, changes in parameters of liver function, carbohydrate metabolism and haemostasis may occur. If the results of relevant tests become abnormal, treatment should be discontinued. An increase in LDL cholesterol and a decrease in HDL cholesterol may occur during Orgatril therapy. During prolonged treatment with progestagens, periodic medical examinations are advisable. As determined by the effects on SHBG, Orgatril has weak androgenic activity, and this is confirmed by the slight signs of virilisation, such as acne and hirsutism, observed in some patients. Patients with any of the following conditions should be kept under close medical supervision: circulatory disorders, or a history of this condition, since a slightly increased risk of some cardiovascular disorders has been reported with estrogen/progestagen containing oral contraceptive preparations, and some forms of severe depression, if likely to be exacerbated by sex steroids.
Contraindications
Pregnancy or suspected pregnancy. Severe liver disease such as cholestatic jaundice or hepatitis, or a history of severe liver disease where liver function tests have not returned to normal, as well as hepatic cell tumours, Rotor syndrome and Dubin-Johnson syndrome. Undiagnosed vaginal bleeding. Rare conditions known to be affected by sex steroids, or a history of these conditions, since they may have first appeared or worsened during pregnancy or use of sex steroids, including herpes gestationis, jaundice of pregnancy, otosclerosis, severe pruritus or porphyria.